Neuralink's Blindsight Receives FDA Breakthrough Device Designation on September 17, 2024

Sep 17, 2024, 07:12 PM

Neuralink, the brain-chip startup founded by Elon Musk, has received the U.S. Food and Drug Administration's (FDA) Breakthrough Device Designation for its brain implant chip named Blindsight on September 17, 2024. This designation is given when preliminary clinical evidence suggests that the device may offer substantial improvement over existing treatments. Blindsight aims to restore vision in individuals who were born blind or have lost their eyesight, including those without optic nerves, provided their visual cortex is intact. The device has already demonstrated success in monkeys and allows patients to control a mouse using only their thoughts. Blindsight is Neuralink's next product after Telepathy.